Skip to content
Disclosery

EXANE DERIVATIVES: APPS position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on APPS, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 19 APPS shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 19 shares
    Change vs previous 13F -839 shares

    <0.01% of the 13F portfolio, value $332.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 858 shares
    Change vs previous 13F -126 shares

    0.01% of the 13F portfolio, value $37,587.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 984 shares
    Change vs previous 13F -280 shares

    0.01% of the 13F portfolio, value $60,012.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 1,264 shares
    Change vs previous 13F -244 shares

    0.02% of the 13F portfolio, value $86,897.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 1,508 shares
    Change vs previous 13F -21 shares

    0.02% of the 13F portfolio, value $97,460.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 1,529 shares
    Change vs previous 13F not available

    0.04% of the 13F portfolio, value $122,865.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).